Imipramine

Generic name: Pronounced as (im ip' ra meen)
Brand names
  • Tofranil®
  • Tofranil® PM
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 09/15/2018

A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as imipramine during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant. Children younger than 18 years of age should not normally take imipramine except to prevent bedwetting, but in some cases, a doctor may decide that imipramine is the best medication to treat a child's condition.

You should know that your mental health may change in unexpected ways when you take imipramine or other antidepressants even if you are an adult over 24 years of age. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; and frenzied abnormal excitement. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Your healthcare provider will want to see you often while you are taking imipramine, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.

The doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with imipramine. Read the information carefully and ask your doctor or pharmacist if you have any questions. You also can obtain the Medication Guide from the FDA website: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273.

No matter your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.

Imipramine tablets and capsules are used to treat depression. Imipramine tablets are also used to prevent bedwetting in children. Imipramine is in a class of medications called tricyclic antidepressants. It treats depression by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance. There is not enough information to explain how imipramine prevents bedwetting.

Imipramine comes as a tablet and a capsule to take by mouth. When imipramine tablets or capsules are used to treat depression, they are usually taken one or more times a day and may be taken with or without food. When imipramine tablets are used to prevent bedwetting in children, they are usually taken one hour before bedtime. Children who wet the bed early in the evening may be given one dose in the mid-afternoon and another dose at bedtime. Try to take imipramine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take imipramine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may start you on a low dose of imipramine and gradually increase your dose.

It may take 1-3 weeks or longer for you to feel the full benefit of imipramine. Continue to take imipramine even if you feel well. Do not stop taking imipramine without talking to your doctor. Your doctor will probably want to decrease your dose gradually.

Imipramine is also used occasionally to treat eating disorders and panic disorders. Talk to your doctor about the possible risks of using this medication for your condition.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Before taking imipramine,

  • tell your doctor and pharmacist if you are allergic to imipramine, any other medications, or any of the ingredients in imipramine tablets or capsules. Ask your doctor or pharmacist for a list of the ingredients.

  • tell your doctor if you are taking a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate), or if you have stopped taking an MAO inhibitor within the past 14 days. Your doctor will probably tell you not to take imipramine. If you stop taking imipramine, you should wait at least 14 days before you start to take an MAO inhibitor.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (blood thinners) such as warfarin (Coumadin, Jantoven); antihistamines; cimetidine (Tagamet); flecainide (Tambocor); levodopa (Sinemet, Larodopa); lithium (Eskalith, Lithobid); medication for high blood pressure, mental illness, nausea, seizures, Parkinson's disease, asthma, colds, or allergies; methylphenidate (Ritalin); muscle relaxants; propafenone (Rhythmol); quinidine; sedatives; selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft); sleeping pills; thyroid medications; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Your doctor may tell you not to take imipramine if you have taken fluoxetine in the past 5 weeks.

  • tell your doctor if you have recently had a heart attack. Your doctor may tell you not to take imipramine.

  • tell your doctor if you are being treated with electroshock therapy (procedure in which small electric shocks are administered to the brain to treat certain mental illnesses), and if you have or have ever had an enlarged prostate (a male reproductive gland), difficulty urinating, seizures, an overactive thyroid gland, or liver, kidney, or heart disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking imipramine, call your doctor.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking imipramine.

  • you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • remember that alcohol can add to the drowsiness caused by this medication.

  • tell your doctor if you use tobacco products. Cigarette smoking may decrease the effectiveness of this medication.

  • plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Imipramine may make your skin sensitive to sunlight.

  • talk to your doctor about the risks and benefits of taking imipramine if you are 65 years of age or older. Older adults should not usually take imipramine because it is not as safe and effective as other medications that can be used to treat the same condition.

  • you should know that imipramine may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule.

  • Imipramine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • drowsiness

    • weakness or tiredness

    • excitement or anxiety

    • nightmares

    • dry mouth

    • skin more sensitive to sunlight than usual

    • changes in appetite or weight

    • constipation

    • difficulty urinating

    • frequent urination

    • changes in sex drive or ability

    • excessive sweating

  • Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately or get emergency medical treatment:

    • jaw, neck, and back muscle spasms

    • slow or difficult speech

    • shuffling walk

    • uncontrollable shaking of a part of the body

    • fever, sore throat, or other signs of infection

    • difficulty breathing or swallowing

    • severe rash

    • yellowing of the skin or eyes

    • irregular heartbeat

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

  • Imipramine may cause other side effects. Tell your doctor if you have any unusual problems while you are taking this medication.

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The metabolism of Imipramine can be decreased when combined with Moxifloxacin.
Repaglinide Repaglinide Imipramine may decrease the hypoglycemic activities of Repaglinide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The metabolism of Imipramine can be increased when combined with Insulin glargine.
Leflunomide Leflunomide The serum concentration of Imipramine can be decreased when it is combined with Leflunomide.
Delavirdine Delavirdine The metabolism of Imipramine can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Imipramine can be decreased when combined with Nevirapine.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Imipramine.
Dolasetron Dolasetron The metabolism of Imipramine can be decreased when combined with Dolasetron.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Imipramine.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Imipramine.
Candesartan Candesartan Imipramine may decrease the antihypertensive activities of Candesartan.
Cilostazol Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Imipramine.
Clopidogrel Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Imipramine resulting in a loss in efficacy.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Imipramine is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The serum concentration of Imipramine can be increased when it is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Imipramine.
Fenofibrate Fenofibrate The metabolism of Imipramine can be decreased when combined with Fenofibrate.
Guanfacine Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Magnesium Hydroxide Magnesium Hydroxide Imipramine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium Oxide Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Imipramine.
Methylergonovine Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Imipramine.
Miglitol Miglitol Imipramine may decrease the hypoglycemic activities of Miglitol.
Mycophenolate Mycophenolate Imipramine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Imipramine is combined with Naratriptan.
Olsalazine Olsalazine Imipramine may decrease the excretion rate of Olsalazine which could result in a higher serum level.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Imipramine.
Penbutolol Penbutolol The metabolism of Imipramine can be decreased when combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Imipramine.
Potassium Potassium Potassium may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone Imipramine may decrease the excretion rate of Prednisone which could result in a higher serum level.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Imipramine.
Ranitidine Ranitidine The metabolism of Ranitidine can be decreased when combined with Imipramine.
Reserpine Reserpine The serum concentration of Reserpine can be increased when it is combined with Imipramine.
Rizatriptan Rizatriptan Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Sumatriptan Sumatriptan Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Tacrolimus Tacrolimus The serum concentration of Imipramine can be increased when it is combined with Tacrolimus.
Tizanidine Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Imipramine.
Triamcinolone Triamcinolone The metabolism of Imipramine can be increased when combined with Triamcinolone.
Zolmitriptan Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Imipramine.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Imipramine which could result in a higher serum level.
Famotidine Injection Famotidine Injection The metabolism of Imipramine can be decreased when combined with Famotidine.
Fluconazole Injection Fluconazole Injection The serum concentration of Imipramine can be increased when it is combined with Fluconazole.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Imipramine which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Imipramine.
Interferon Beta-1b Injection Interferon Beta-1b Injection The metabolism of Imipramine can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The metabolism of Imipramine can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection Levofloxacin Injection The metabolism of Imipramine can be decreased when combined with Levofloxacin.
Meperidine Injection Meperidine Injection The metabolism of Imipramine can be decreased when combined with Meperidine.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Imipramine.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Metronidazole.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Imipramine.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Imipramine may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine Amphetamine may decrease the sedative and stimulatory activities of Imipramine.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cyclosporine Cyclosporine The metabolism of Imipramine can be decreased when combined with Cyclosporine.
Ondansetron Ondansetron The metabolism of Ondansetron can be decreased when combined with Imipramine.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Imipramine is combined with Granisetron.
Torsemide Torsemide Imipramine may increase the excretion rate of Torasemide which could result in a lower serum level and potentially a reduction in efficacy.
Alosetron Alosetron The metabolism of Imipramine can be decreased when combined with Alosetron.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Dofetilide.
Entacapone Entacapone The metabolism of Imipramine can be decreased when combined with Entacapone.
Eprosartan Eprosartan Imipramine may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine Hydroxychloroquine The metabolism of Imipramine can be decreased when combined with Hydroxychloroquine.
Meloxicam Meloxicam Imipramine may decrease the excretion rate of Meloxicam which could result in a higher serum level.
Oxcarbazepine Oxcarbazepine The metabolism of Imipramine can be decreased when combined with Oxcarbazepine.
Pantoprazole Pantoprazole The metabolism of Imipramine can be decreased when combined with Pantoprazole.
Telmisartan Telmisartan The metabolism of Imipramine can be decreased when combined with Telmisartan.
Temozolomide Temozolomide Imipramine may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Zaleplon Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Anakinra Anakinra The metabolism of Imipramine can be increased when combined with Anakinra.
Desloratadine Desloratadine Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Imipramine.
Rivastigmine Rivastigmine The therapeutic efficacy of Imipramine can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Imipramine can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Imipramine is combined with Glycopyrronium.
Modafinil Modafinil The metabolism of Imipramine can be decreased when combined with Modafinil.
Perindopril Perindopril Imipramine may decrease the antihypertensive activities of Perindopril.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Imipramine may decrease the excretion rate of Choline magnesium trisalicylate which could result in a higher serum level.
Sirolimus Sirolimus The metabolism of Sirolimus can be decreased when combined with Imipramine.
Dutasteride Dutasteride The risk or severity of hypertension can be increased when Imipramine is combined with Dutasteride.
Epinephrine Injection Epinephrine Injection Imipramine may increase the vasopressor activities of Epinephrine.
Eplerenone Eplerenone Imipramine may increase the excretion rate of Eplerenone which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Escitalopram.
Olmesartan Olmesartan Imipramine may decrease the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide The serum concentration of Imipramine can be increased when it is combined with Zonisamide.
Adalimumab Injection Adalimumab Injection The metabolism of Imipramine can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Atomoxetine Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Imipramine.
Dexmethylphenidate Dexmethylphenidate The serum concentration of Imipramine can be increased when it is combined with Dexmethylphenidate.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Almotriptan Almotriptan The metabolism of Imipramine can be decreased when combined with Almotriptan.
Eletriptan Eletriptan The metabolism of Imipramine can be decreased when combined with Eletriptan.
Mefloquine Mefloquine The metabolism of Imipramine can be decreased when combined with Mefloquine.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Imipramine.
Vardenafil Vardenafil The serum concentration of Imipramine can be increased when it is combined with Vardenafil.
Alfuzosin Alfuzosin Alfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Aprepitant Aprepitant The metabolism of Imipramine can be decreased when combined with Aprepitant.
Emtricitabine Emtricitabine Imipramine may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection Interferon Beta-1a Subcutaneous Injection The metabolism of Imipramine can be decreased when combined with Interferon beta-1a.
Memantine Memantine The metabolism of Imipramine can be decreased when combined with Memantine.
Tegaserod Tegaserod The metabolism of Imipramine can be decreased when combined with Tegaserod.
Tadalafil Tadalafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Imipramine is combined with Tadalafil.
Frovatriptan Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Imipramine.
Gemifloxacin Gemifloxacin The metabolism of Imipramine can be decreased when combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Imipramine can be decreased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Apomorphine.
Infliximab Injection Infliximab Injection The metabolism of Imipramine can be increased when combined with Infliximab.
Protriptyline Protriptyline The metabolism of Imipramine can be decreased when combined with Protriptyline.
Rifaximin Rifaximin The metabolism of Imipramine can be increased when combined with Rifaximin.
Duloxetine Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Imipramine is combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Norethisterone can be increased when combined with Imipramine.
Tinidazole Tinidazole Imipramine may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Trospium Trospium The metabolism of Trospium can be decreased when combined with Imipramine.
Bosentan Bosentan Imipramine may decrease the antihypertensive activities of Bosentan.
Cefditoren Cefditoren Imipramine may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cinacalcet Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Imipramine.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Erlotinib Erlotinib The metabolism of Imipramine can be decreased when combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Imipramine is combined with Eszopiclone.
Ganciclovir Ganciclovir Imipramine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection Imipramine may decrease the hypoglycemic activities of Insulin aspart.
Ribavirin Ribavirin Imipramine may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Solifenacin Solifenacin The metabolism of Imipramine can be decreased when combined with Solifenacin.
Valganciclovir Valganciclovir Imipramine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole Voriconazole The metabolism of Imipramine can be decreased when combined with Voriconazole.
Adefovir Adefovir Adefovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine Amphetamine may decrease the sedative and stimulatory activities of Imipramine.
Entecavir Entecavir The metabolism of Entecavir can be decreased when combined with Imipramine.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The metabolism of Imipramine can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Imipramine can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Imipramine.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Exenatide Injection Exenatide Injection Imipramine may decrease the hypoglycemic activities of Exenatide.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imipramine.
Isocarboxazid Isocarboxazid Imipramine may increase the serotonergic activities of Isocarboxazid.
Ramelteon Ramelteon The metabolism of Imipramine can be decreased when combined with Ramelteon.
Darifenacin Darifenacin The metabolism of Darifenacin can be decreased when combined with Imipramine.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Imipramine.
Pregabalin Pregabalin The therapeutic efficacy of Imipramine can be increased when used in combination with Pregabalin.
Deferasirox Deferasirox The serum concentration of Imipramine can be increased when it is combined with Deferasirox.
Phenylephrine Phenylephrine Imipramine may increase the vasopressor activities of Phenylephrine.
Tipranavir Tipranavir The metabolism of Imipramine can be decreased when combined with Tipranavir.
Felbamate Felbamate The metabolism of Imipramine can be decreased when combined with Felbamate.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection Imipramine may decrease the hypoglycemic activities of Insulin detemir.
Ranolazine Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Imipramine.
Abatacept Injection Abatacept Injection The metabolism of Imipramine can be increased when combined with Abatacept.
Rasagiline Rasagiline Rasagiline may increase the serotonergic activities of Imipramine.
Imatinib Imatinib The metabolism of Imipramine can be decreased when combined with Imatinib.
Sitagliptin Sitagliptin Imipramine may decrease the hypoglycemic activities of Sitagliptin.
Varenicline Varenicline The excretion of Varenicline can be decreased when combined with Imipramine.
Gefitinib Gefitinib The metabolism of Imipramine can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Imipramine is combined with Salbutamol.
Paliperidone Paliperidone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Bortezomib Bortezomib The metabolism of Imipramine can be decreased when combined with Bortezomib.
Clofarabine Injection Clofarabine Injection The serum concentration of Clofarabine can be increased when it is combined with Imipramine.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The metabolism of Imipramine can be increased when combined with Insulin glulisine.
Lubiprostone Lubiprostone Imipramine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The serum concentration of Oxaliplatin can be increased when it is combined with Imipramine.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Imipramine.
Primaquine Primaquine The metabolism of Imipramine can be decreased when combined with Primaquine.
Aliskiren Aliskiren Imipramine may decrease the antihypertensive activities of Aliskiren.
Bismuth Subsalicylate Bismuth Subsalicylate Imipramine may increase the neurotoxic activities of Bismuth subsalicylate.
Pemetrexed Injection Pemetrexed Injection Imipramine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lisdexamfetamine Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Imipramine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Imipramine.
Sorafenib Sorafenib The metabolism of Sorafenib can be decreased when combined with Imipramine.
Sunitinib Sunitinib The metabolism of Sunitinib can be decreased when combined with Imipramine.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lapatinib Lapatinib The serum concentration of Lapatinib can be increased when it is combined with Imipramine.
Levocetirizine Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Pegaptanib Injection Pegaptanib Injection Imipramine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Imipramine.
Mexiletine Mexiletine The metabolism of Imipramine can be decreased when combined with Mexiletine.
Armodafinil Armodafinil The metabolism of Imipramine can be decreased when combined with Armodafinil.
Azacitidine Injection Azacitidine Injection Imipramine may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Imipramine.
Temsirolimus Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Imipramine.
Lenalidomide Lenalidomide Imipramine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Nilotinib Nilotinib The metabolism of Imipramine can be decreased when combined with Nilotinib.
Toremifene Toremifene The serum concentration of Toremifene can be increased when it is combined with Imipramine.
Budesonide Budesonide Imipramine may decrease the excretion rate of Budesonide which could result in a higher serum level.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Imipramine can be decreased when combined with Chloramphenicol.
Desmopressin Desmopressin The risk or severity of hyponatremia and water intoxication can be increased when Imipramine is combined with Desmopressin.
Betaine Betaine The therapeutic efficacy of Imipramine can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum Toxin Type B.
Doripenem Injection Doripenem Injection Imipramine may decrease the excretion rate of Doripenem which could result in a higher serum level.
Etravirine Etravirine The serum concentration of Etravirine can be decreased when it is combined with Imipramine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Imipramine.
Desvenlafaxine Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Imipramine.
Cevimeline Cevimeline The metabolism of Imipramine can be decreased when combined with Cevimeline.
Nebivolol Nebivolol The metabolism of Imipramine can be decreased when combined with Nebivolol.
Tretinoin Tretinoin The metabolism of Tretinoin can be decreased when combined with Imipramine.
Bendamustine Injection Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Imipramine.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Imipramine.
Certolizumab Injection Certolizumab Injection The metabolism of Imipramine can be increased when combined with Certolizumab pegol.
Irinotecan Injection Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Imipramine.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Imipramine.
Methylnaltrexone Injection Methylnaltrexone Injection Imipramine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Imipramine.
Silodosin Silodosin Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Midazolam Midazolam Midazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Naltrexone Injection Naltrexone Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Naltrexone.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Imipramine which could result in a higher serum level.
Eltrombopag Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Imipramine.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Imipramine is combined with Milnacipran.
Dexlansoprazole Dexlansoprazole The metabolism of Imipramine can be decreased when combined with Dexlansoprazole.
Plerixafor Injection Plerixafor Injection Imipramine may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Sodium Phosphate Sodium Phosphate The risk or severity of seizure can be increased when Imipramine is combined with Sodium phosphate, monobasic.
Fesoterodine Fesoterodine The metabolism of Imipramine can be decreased when combined with Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imipramine.
Betaxolol Betaxolol The metabolism of Imipramine can be decreased when combined with Betaxolol.
Iloperidone Iloperidone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.
Prasugrel Prasugrel The metabolism of Prasugrel can be decreased when combined with Imipramine.
Lacosamide Lacosamide The metabolism of Imipramine can be decreased when combined with Lacosamide.
Everolimus Everolimus The metabolism of Imipramine can be decreased when combined with Everolimus.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone Dronedarone Dronedarone may increase the QTc-prolonging activities of Imipramine.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.
Pralatrexate Injection Pralatrexate Injection Imipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection The metabolism of Imipramine can be decreased when combined with Palonosetron.
Saxagliptin Saxagliptin Imipramine may decrease the hypoglycemic activities of Saxagliptin.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Topotecan Topotecan Imipramine may decrease the excretion rate of Topotecan which could result in a higher serum level.
Golimumab Injection Golimumab Injection The metabolism of Imipramine can be increased when combined with Golimumab.
Pazopanib Pazopanib The metabolism of Imipramine can be decreased when combined with Pazopanib.
Asenapine Asenapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.
Vigabatrin Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Imipramine.
Oxymorphone Oxymorphone The metabolism of Imipramine can be decreased when combined with Oxymorphone.
Liraglutide Injection Liraglutide Injection Imipramine may decrease the hypoglycemic activities of Liraglutide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Imipramine can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine The risk or severity of seizure can be increased when Imipramine is combined with Dalfampridine.
Fingolimod Fingolimod The metabolism of Fingolimod can be decreased when combined with Imipramine.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Imipramine.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.
Cabazitaxel Injection Cabazitaxel Injection The serum concentration of Imipramine can be increased when it is combined with Cabazitaxel.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Lurasidone Lurasidone Imipramine may increase the hypotensive activities of Lurasidone.
Acetaminophen Injection Acetaminophen Injection Imipramine may increase the hepatotoxic activities of Acetaminophen.
Vilazodone Vilazodone The metabolism of Vilazodone can be decreased when combined with Imipramine.
Ipilimumab Injection Ipilimumab Injection Imipramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Terbutaline Injection Terbutaline Injection The therapeutic efficacy of Imipramine can be decreased when used in combination with Terbutaline.
Azilsartan Azilsartan The risk or severity of adverse effects can be increased when Imipramine is combined with Azilsartan medoxomil.
Roflumilast Roflumilast Imipramine may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Linagliptin Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Imipramine.
Rilpivirine Rilpivirine The metabolism of Imipramine can be decreased when combined with Rilpivirine.
Telaprevir Telaprevir The serum concentration of Imipramine can be increased when it is combined with Glecaprevir.
Potassium Iodide Potassium Iodide The risk or severity of Cardiac Arrhythmia can be increased when Potassium Iodide is combined with Imipramine.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Imipramine.
Abiraterone Abiraterone The serum concentration of Imipramine can be increased when it is combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imipramine.
Rivaroxaban Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Imipramine.
Ticagrelor Ticagrelor The serum concentration of Imipramine can be increased when it is combined with Ticagrelor.
Ruxolitinib Ruxolitinib Imipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib Vandetanib The serum concentration of Vandetanib can be increased when it is combined with Imipramine.
Clobazam Clobazam The metabolism of Imipramine can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The serum concentration of Imipramine can be increased when it is combined with Vemurafenib.
Vismodegib Vismodegib The metabolism of Imipramine can be decreased when combined with Vismodegib.
Ivacaftor Ivacaftor The serum concentration of Imipramine can be increased when it is combined with Ivacaftor.
Deferiprone Deferiprone Imipramine may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib Axitinib The metabolism of Imipramine can be decreased when combined with Axitinib.
Crizotinib Crizotinib The serum concentration of Imipramine can be increased when it is combined with Crizotinib.
Cabergoline Cabergoline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Naloxone Injection Naloxone Injection Imipramine may decrease the excretion rate of Naloxone which could result in a higher serum level.
Ambrisentan Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Imipramine.
Fondaparinux Injection Fondaparinux Injection Imipramine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Ezogabine Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Carfilzomib Injection Carfilzomib Injection The serum concentration of Imipramine can be increased when it is combined with Carfilzomib.
Iloprost Iloprost The risk or severity of adverse effects can be increased when Imipramine is combined with Iloprost.
Enzalutamide Enzalutamide The serum concentration of Imipramine can be increased when it is combined with Enzalutamide.
Mirabegron Mirabegron The risk or severity of urinary retention can be increased when Imipramine is combined with Mirabegron.
Regorafenib Regorafenib The serum concentration of Imipramine can be increased when it is combined with Regorafenib.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Imipramine.
Teriflunomide Teriflunomide The serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.
Lorcaserin Lorcaserin Imipramine may decrease the hypoglycemic activities of Mecasermin.
Teduglutide Injection Teduglutide Injection Imipramine may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Imipramine is combined with Bedaquiline.
Alogliptin Alogliptin The metabolism of Imipramine can be decreased when combined with Alogliptin.
Ponatinib Ponatinib The metabolism of Imipramine can be decreased when combined with Ponatinib.
Pomalidomide Pomalidomide The metabolism of Imipramine can be decreased when combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The serum concentration of Imipramine can be increased when it is combined with Trastuzumab emtansine.
Apixaban Apixaban The metabolism of Imipramine can be decreased when combined with Apixaban.
Canagliflozin Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Imipramine.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Imipramine can be decreased when combined with Ospemifene.
Trametinib Trametinib Imipramine may decrease the excretion rate of Trametinib which could result in a higher serum level.
Dolutegravir Dolutegravir The serum concentration of Imipramine can be increased when it is combined with Dolutegravir.
Afatinib Afatinib The serum concentration of Imipramine can be increased when it is combined with Afatinib.
Levomilnacipran Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Imipramine.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Imipramine which could result in a higher serum level.
Vortioxetine Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Imipramine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Imipramine.
Lomitapide Lomitapide The serum concentration of Imipramine can be increased when it is combined with Lomitapide.
Avanafil Avanafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Imipramine.
Ketorolac Injection Ketorolac Injection Imipramine may decrease the excretion rate of Ketorolac which could result in a higher serum level.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Obinutuzumab.
Simeprevir Simeprevir The serum concentration of Imipramine can be increased when it is combined with Simeprevir.
Sofosbuvir Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Imipramine.
Dapagliflozin Dapagliflozin The metabolism of Imipramine can be decreased when combined with Dapagliflozin.
Apremilast Apremilast The metabolism of Apremilast can be increased when combined with Imipramine.
Droxidopa Droxidopa Imipramine may increase the vasopressor activities of Droxidopa.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Imipramine can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection Imipramine may decrease the hypoglycemic activities of Albiglutide.
Eslicarbazepine Eslicarbazepine The metabolism of Imipramine can be decreased when combined with Eslicarbazepine.
Belinostat Injection Belinostat Injection The metabolism of Imipramine can be increased when combined with Belinostat.
Idelalisib Idelalisib The serum concentration of Imipramine can be increased when it is combined with Idelalisib.
Testosterone Injection Testosterone Injection The metabolism of Testosterone can be decreased when combined with Imipramine.
Oritavancin Injection Oritavancin Injection The metabolism of Imipramine can be decreased when combined with Oritavancin.
Empagliflozin Empagliflozin Imipramine may decrease the hypoglycemic activities of Empagliflozin.
Vorapaxar Vorapaxar The serum concentration of Imipramine can be increased when it is combined with Vorapaxar.
Hydrocodone Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Suvorexant Suvorexant Imipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection Imipramine may decrease the hypoglycemic activities of Dulaglutide.
Edoxaban Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Imipramine.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The metabolism of Imipramine can be decreased when combined with Peginterferon beta-1a.
Olaparib Olaparib The metabolism of Imipramine can be increased when combined with Olaparib.
Methamphetamine Methamphetamine Metamfetamine may decrease the sedative and stimulatory activities of Imipramine.
Tasimelteon Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Riociguat Riociguat Imipramine may decrease the antihypertensive activities of Riociguat.
Pirfenidone Pirfenidone The serum concentration of Pirfenidone can be increased when it is combined with Imipramine.
Nintedanib Nintedanib The serum concentration of Imipramine can be increased when it is combined with Nintedanib.
Secukinumab Injection Secukinumab Injection The metabolism of Imipramine can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection Imipramine may increase the hypotensive activities of Risperidone.
Palbociclib Palbociclib The serum concentration of Imipramine can be increased when it is combined with Palbociclib.
Insulin Human Inhalation Insulin Human Inhalation The metabolism of Imipramine can be increased when combined with Insulin human.
Lenvatinib Lenvatinib The metabolism of Imipramine can be decreased when combined with Lenvatinib.
Naloxegol Naloxegol The metabolism of Imipramine can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Imipramine can be decreased when combined with Panobinostat.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Dinutuximab.
Haloperidol Injection Haloperidol Injection The serum concentration of Haloperidol can be increased when it is combined with Imipramine.
Ivabradine Ivabradine Ivabradine may increase the QTc-prolonging activities of Imipramine.
Amiloride Amiloride Amiloride may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection Isavuconazonium Injection The serum concentration of Imipramine can be increased when it is combined with Isavuconazonium.
Macitentan Macitentan Imipramine may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Imipramine.
Rolapitant Rolapitant The metabolism of Imipramine can be decreased when combined with Rolapitant.
Daclatasvir Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Imipramine.
Brexpiprazole Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Imipramine.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Imipramine.
Cariprazine Cariprazine The metabolism of Cariprazine can be decreased when combined with Imipramine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Imipramine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Imipramine is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The metabolism of Imipramine can be increased when combined with Insulin degludec.
Cobimetinib Cobimetinib The serum concentration of Imipramine can be increased when it is combined with Cobimetinib.
Trabectedin Injection Trabectedin Injection The metabolism of Imipramine can be decreased when combined with Trabectedin.
Osimertinib Osimertinib The serum concentration of Imipramine can be decreased when it is combined with Osimertinib.
Ixazomib Ixazomib Imipramine may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Rifapentine Rifapentine The metabolism of Imipramine can be increased when combined with Rifapentine.
Lesinurad Lesinurad Imipramine may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dexamethasone Injection Dexamethasone Injection The metabolism of Imipramine can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Venetoclax Venetoclax The serum concentration of Imipramine can be increased when it is combined with Venetoclax.
Cobicistat Cobicistat The serum concentration of Imipramine can be increased when it is combined with Cobicistat.
Midodrine Midodrine Midodrine may increase the vasopressor activities of Imipramine.
Selexipag Selexipag The serum concentration of Selexipag can be increased when it is combined with Imipramine.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Imipramine is combined with Pimavanserin.
Obeticholic Acid Obeticholic Acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Imipramine.
Diphenhydramine Injection Diphenhydramine Injection The metabolism of Imipramine can be decreased when combined with Diphenhydramine.
Furosemide Injection Furosemide Injection Imipramine may decrease the excretion rate of Furosemide which could result in a higher serum level.
Rucaparib Rucaparib The metabolism of Imipramine can be decreased when combined with Rucaparib.
Lixisenatide Injection Lixisenatide Injection Imipramine may decrease the hypoglycemic activities of Lixisenatide.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Imipramine.
Deutetrabenazine Deutetrabenazine The metabolism of Imipramine can be decreased when combined with Deutetrabenazine.
Valbenazine Valbenazine The metabolism of Imipramine can be decreased when combined with Valbenazine.
Safinamide Safinamide The metabolism of Imipramine can be decreased when combined with Safinamide.
Naldemedine Naldemedine Imipramine may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin Midostaurin The metabolism of Imipramine can be decreased when combined with Midostaurin.
Neratinib Neratinib The serum concentration of Imipramine can be increased when it is combined with Neratinib.
Enasidenib Enasidenib The metabolism of Imipramine can be decreased when combined with Enasidenib.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The serum concentration of Imipramine can be increased when it is combined with Inotuzumab ozogamicin.
Benznidazole Benznidazole Imipramine may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Copanlisib Injection Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Imipramine.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Imipramine is combined with Delafloxacin.
Betrixaban Betrixaban The serum concentration of Imipramine can be increased when it is combined with Betrixaban.
Letermovir Letermovir The metabolism of Imipramine can be decreased when combined with Letermovir.
Semaglutide Injection Semaglutide Injection Imipramine may decrease the hypoglycemic activities of Semaglutide.
Tetrabenazine Tetrabenazine The metabolism of Imipramine can be decreased when combined with Tetrabenazine.
Ertugliflozin Ertugliflozin Imipramine may decrease the hypoglycemic activities of Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Imipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Imipramine can be increased when it is combined with Apalutamide.
Fostamatinib Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Imipramine.
Avatrombopag Avatrombopag The serum concentration of Imipramine can be increased when it is combined with Avatrombopag.
Baricitinib Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Imipramine.
Lofexidine Lofexidine The therapeutic efficacy of Imipramine can be increased when used in combination with Lofexidine.
Plazomicin Injection Plazomicin Injection Imipramine may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Imipramine.
Encorafenib Encorafenib The metabolism of Imipramine can be decreased when combined with Encorafenib.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Imipramine.
Ivosidenib Ivosidenib The serum concentration of Ivosidenib can be increased when it is combined with Imipramine.
Lusutrombopag Lusutrombopag The serum concentration of Imipramine can be increased when it is combined with Lusutrombopag.
Elagolix Elagolix The metabolism of Imipramine can be decreased when combined with Elagolix.
Tafenoquine Tafenoquine The metabolism of Imipramine can be decreased when combined with Tafenoquine.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Imipramine.
Dacomitinib Dacomitinib The metabolism of Imipramine can be decreased when combined with Dacomitinib.
Duvelisib Duvelisib The serum concentration of Imipramine can be increased when it is combined with Duvelisib.
Omadacycline Omadacycline The serum concentration of Imipramine can be increased when it is combined with Omadacycline.
Sarecycline Sarecycline The serum concentration of Imipramine can be increased when it is combined with Sarecycline.
Stiripentol Stiripentol The metabolism of Imipramine can be decreased when combined with Stiripentol.
Talazoparib Talazoparib The serum concentration of Imipramine can be increased when it is combined with Talazoparib.
Gilteritinib Gilteritinib The therapeutic efficacy of Imipramine can be decreased when used in combination with Gilteritinib.
Glasdegib Glasdegib The serum concentration of Glasdegib can be increased when it is combined with Imipramine.
Lorlatinib Lorlatinib The metabolism of Imipramine can be decreased when combined with Lorlatinib.
Larotrectinib Larotrectinib The serum concentration of Imipramine can be increased when it is combined with Larotrectinib.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Imipramine.
Rifamycin Rifamycin The serum concentration of Imipramine can be increased when it is combined with Rifamycin.
Prucalopride Prucalopride Imipramine may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Imipramine.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Imipramine can be increased when combined with Emapalumab.
Siponimod Siponimod The risk or severity of hypertension can be increased when Imipramine is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Imipramine.
Erdafitinib Erdafitinib The serum concentration of Imipramine can be increased when it is combined with Erdafitinib.
Esomeprazole Injection Esomeprazole Injection The metabolism of Imipramine can be decreased when combined with Esomeprazole.
Alpelisib Alpelisib The metabolism of Imipramine can be decreased when combined with Alpelisib.
Brexanolone Injection Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Imipramine.
Darolutamide Darolutamide The serum concentration of Imipramine can be increased when it is combined with Darolutamide.
Triclabendazole Triclabendazole The metabolism of Imipramine can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Entrectinib.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Imipramine.
Pitolisant Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Imipramine.
Fedratinib Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Imipramine.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Imipramine.
Phenytoin Injection Phenytoin Injection The metabolism of Phenytoin can be decreased when combined with Imipramine.
Fosphenytoin Injection Fosphenytoin Injection The metabolism of Imipramine can be increased when combined with Fosphenytoin.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Imipramine can be increased when it is combined with Enfortumab vedotin.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Imipramine.
Voxelotor Voxelotor The metabolism of Voxelotor can be decreased when combined with Imipramine.
Lumateperone Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Imipramine can be increased when it is combined with Ubrogepant.
Tazemetostat Tazemetostat The serum concentration of Imipramine can be increased when it is combined with Tazemetostat.
Cenobamate Cenobamate The serum concentration of Cenobamate can be decreased when it is combined with Imipramine.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Imipramine.
Rimegepant Rimegepant The serum concentration of Imipramine can be increased when it is combined with Rimegepant.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Imipramine.
Remdesivir Injection Remdesivir Injection The serum concentration of Imipramine can be increased when it is combined with Remdesivir.
Ripretinib Ripretinib The serum concentration of Imipramine can be increased when it is combined with Ripretinib.
Selpercatinib Selpercatinib The risk or severity of hypertension can be increased when Imipramine is combined with Selpercatinib.
Capmatinib Capmatinib The serum concentration of Imipramine can be increased when it is combined with Capmatinib.
Lemborexant Lemborexant The serum concentration of Imipramine can be decreased when it is combined with Lemborexant.
Daratumumab and Hyaluronidase-fihj Injection Daratumumab and Hyaluronidase-fihj Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Imipramine.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Imipramine.
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imipramine.
Belantamab Mafodotin-blmf Injection Belantamab Mafodotin-blmf Injection The serum concentration of Imipramine can be increased when it is combined with Belantamab mafodotin.
Pralsetinib Pralsetinib The serum concentration of Imipramine can be increased when it is combined with Pralsetinib.
Opicapone Opicapone The metabolism of Imipramine can be increased when combined with Opicapone.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Imipramine can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Imipramine is combined with Naxitamab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Imipramine.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine Viloxazine The metabolism of Imipramine can be decreased when combined with Viloxazine.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Theophylline Theophylline The metabolism of Imipramine can be decreased when combined with Theophylline.
Fenoprofen Fenoprofen Imipramine may decrease the excretion rate of Fenoprofen which could result in a higher serum level.
Indomethacin Indomethacin The metabolism of Imipramine can be decreased when combined with Indomethacin.
Mefenamic Acid Mefenamic Acid Imipramine may decrease the excretion rate of Mefenamic acid which could result in a higher serum level.
Naproxen Naproxen The metabolism of Naproxen can be decreased when combined with Imipramine.
Tolmetin Tolmetin Imipramine may decrease the excretion rate of Tolmetin which could result in a higher serum level.
Sulindac Sulindac Imipramine may decrease the excretion rate of Sulindac which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Imipramine.
Isotretinoin Isotretinoin Imipramine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Imipramine which could result in a higher serum level.
Hydroxyurea Hydroxyurea The metabolism of Imipramine can be decreased when combined with Hydroxyurea.
Floxuridine Floxuridine Floxuridine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Phenobarbital Phenobarbital The metabolism of Imipramine can be decreased when combined with Phenobarbital.
Metaxalone Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Imipramine which could result in a higher serum level.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Imipramine is combined with Levorphanol.
Primidone Primidone The metabolism of Imipramine can be increased when combined with Primidone.
Methsuximide Methsuximide The metabolism of Methsuximide can be decreased when combined with Imipramine.
Diethylpropion Diethylpropion Diethylpropion may decrease the sedative and stimulatory activities of Imipramine.
Chlorpromazine Chlorpromazine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Chlorpromazine.
Diazepam Diazepam The metabolism of Imipramine can be decreased when combined with Diazepam.
Oxazepam Oxazepam Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Flurazepam Flurazepam Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Clorazepate Clorazepate Clorazepic acid may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lorazepam Lorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Phenoxybenzamine Phenoxybenzamine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine.
Carmustine Carmustine The metabolism of Carmustine can be decreased when combined with Imipramine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Amantadine.
Codeine Codeine The metabolism of Imipramine can be decreased when combined with Codeine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Imipramine.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Imipramine is combined with Chlordiazepoxide.
Bromocriptine Bromocriptine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Metaproterenol Metaproterenol The risk or severity of hypertension can be increased when Imipramine is combined with Orciprenaline.
Tranylcypromine Tranylcypromine The metabolism of Tranylcypromine can be decreased when combined with Imipramine.
Phenelzine Phenelzine The metabolism of Imipramine can be decreased when combined with Phenelzine.
Procarbazine Procarbazine Procarbazine may increase the serotonergic activities of Imipramine.
Ergoloid Mesylates Ergoloid Mesylates Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Tetracycline Tetracycline Imipramine may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Prochlorperazine Prochlorperazine The metabolism of Imipramine can be decreased when combined with Prochlorperazine.
Thioridazine Thioridazine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioridazine.
Trifluoperazine Trifluoperazine Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dapsone Dapsone The metabolism of Imipramine can be decreased when combined with Dapsone.
Sulfadiazine Sulfadiazine Imipramine may decrease the hypoglycemic activities of Sulfadiazine.
Oxycodone Oxycodone The metabolism of Imipramine can be decreased when combined with Oxycodone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Imipramine.
Oxybutynin Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Imipramine.
Benztropine Benztropine The metabolism of Imipramine can be decreased when combined with Benzatropine.
Maprotiline Maprotiline The metabolism of Maprotiline can be decreased when combined with Imipramine.
Ibuprofen Ibuprofen Imipramine may decrease the excretion rate of Ibuprofen which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl Imipramine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The metabolism of Perphenazine can be decreased when combined with Imipramine.
Azathioprine Azathioprine The metabolism of Azathioprine can be decreased when combined with Imipramine.
Fluphenazine Fluphenazine The serum concentration of Imipramine can be increased when it is combined with Fluphenazine.
Phentermine Phentermine Phentermine may decrease the sedative and stimulatory activities of Imipramine.
Methylphenidate Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.
Amoxapine Amoxapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.
Sulfasalazine Sulfasalazine Imipramine may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.
Hydrocortisone Hydrocortisone The metabolism of Imipramine can be increased when combined with Hydrocortisone.
Doxorubicin Doxorubicin The metabolism of Imipramine can be decreased when combined with Doxorubicin.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Imipramine can be decreased when used in combination with Mechlorethamine.
Dactinomycin Dactinomycin The serum concentration of Imipramine can be increased when it is combined with Dactinomycin.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Imipramine can be decreased when used in combination with Pyridostigmine.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Carbamazepine Carbamazepine The metabolism of Imipramine can be increased when combined with Carbamazepine.
Molindone Molindone The risk or severity of adverse effects can be increased when Imipramine is combined with Molindone.
Methyldopa Methyldopa The therapeutic efficacy of Methyldopa can be decreased when used in combination with Imipramine.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Imipramine.
Prazosin Prazosin Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.
Hydralazine Hydralazine Imipramine may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine Cimetidine The metabolism of Imipramine can be decreased when combined with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Warfarin Warfarin The metabolism of Warfarin can be decreased when combined with Imipramine.
Clonazepam Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Loperamide Loperamide The metabolism of Imipramine can be decreased when combined with Loperamide.
Promethazine Promethazine The metabolism of Imipramine can be decreased when combined with Promethazine.
Meclofenamate Meclofenamate Imipramine may decrease the excretion rate of Meclofenamic acid which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Imipramine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Griseofulvin Griseofulvin The metabolism of Imipramine can be increased when combined with Griseofulvin.
Digoxin Digoxin Digoxin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Loxapine Loxapine The serum concentration of Imipramine can be increased when it is combined with Loxapine.
Chloroquine Chloroquine The metabolism of Imipramine can be decreased when combined with Chloroquine.
Quinine Quinine The metabolism of Imipramine can be decreased when combined with Quinine.
Ethosuximide Ethosuximide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Triamterene Triamterene The metabolism of Triamterene can be decreased when combined with Imipramine.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Imipramine.
Sulfinpyrazone Sulfinpyrazone The metabolism of Imipramine can be increased when combined with Sulfinpyrazone.
Chlorothiazide Chlorothiazide Imipramine may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Imipramine may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Imipramine may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection Clindamycin Injection Imipramine may increase the neurotoxic activities of Clindamycin.
Secobarbital Secobarbital The metabolism of Imipramine can be increased when combined with Secobarbital.
Desipramine Desipramine The metabolism of Desipramine can be decreased when combined with Imipramine.
Amitriptyline Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Imipramine.
Probenecid Probenecid The metabolism of Imipramine can be decreased when combined with Probenecid.
Quinidine Quinidine Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Procainamide Procainamide The metabolism of Procainamide can be decreased when combined with Imipramine.
Isoniazid Isoniazid The metabolism of Imipramine can be decreased when combined with Isoniazid.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Imipramine which could result in a higher serum level.
Rifampin Rifampin The serum concentration of Imipramine can be decreased when it is combined with Rifampicin.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imipramine.
Tamoxifen Tamoxifen The metabolism of Imipramine can be decreased when combined with Tamoxifen.
Butabarbital Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Levothyroxine Levothyroxine The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Imipramine.
Liothyronine Liothyronine The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Imipramine.
Methimazole Methimazole The risk or severity of Cardiac Arrhythmia can be increased when Methimazole is combined with Imipramine.
Propylthiouracil Propylthiouracil The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Imipramine.
Chlorpropamide Chlorpropamide Imipramine may decrease the hypoglycemic activities of Chlorpropamide.
Glucagon Injection Glucagon Injection Imipramine may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide Tolbutamide Imipramine may decrease the hypoglycemic activities of Tolbutamide.
Tolazamide Tolazamide Imipramine may decrease the hypoglycemic activities of Tolazamide.
Dextromethorphan Dextromethorphan The metabolism of Imipramine can be decreased when combined with Dextromethorphan.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Imipramine is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Imipramine can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of CNS depression and hypotonia can be increased when Baclofen is combined with Imipramine.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Imipramine.
Clemastine Clemastine The metabolism of Imipramine can be decreased when combined with Clemastine.
Chlorpheniramine Chlorpheniramine The metabolism of Imipramine can be decreased when combined with Chlorpheniramine.
Brompheniramine Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Meclizine Meclizine The metabolism of Imipramine can be decreased when combined with Meclizine.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Imipramine which could result in a higher serum level.
Methyclothiazide Methyclothiazide Methyclothiazide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide Imipramine may decrease the excretion rate of Hydrochlorothiazide which could result in a higher serum level.
Dantrolene Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Chlorzoxazone Chlorzoxazone The metabolism of Imipramine can be decreased when combined with Chlorzoxazone.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.
Methocarbamol Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Imipramine.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Imipramine.
Minoxidil Minoxidil Imipramine may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Imipramine.
Nortriptyline Nortriptyline Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Imipramine which could result in a higher serum level.
Phytonadione Phytonadione Imipramine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Nadolol Nadolol The metabolism of Imipramine can be decreased when combined with Nadolol.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Nalbuphine.
Allopurinol Allopurinol Allopurinol may decrease the excretion rate of Imipramine which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine.
Trimethobenzamide Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Clomiphene Clomiphene The serum concentration of Imipramine can be increased when it is combined with Clomifene.
Flavoxate Flavoxate Imipramine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The metabolism of Fluorouracil can be decreased when combined with Imipramine.
Colchicine Colchicine The metabolism of Imipramine can be decreased when combined with Colchicine.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dacarbazine Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Imipramine.
Acetazolamide Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Imipramine.
Ketoconazole Ketoconazole The metabolism of Imipramine can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Thiotepa Injection Thiotepa Injection The metabolism of Imipramine can be decreased when combined with Thiotepa.
Vincristine Injection Vincristine Injection The metabolism of Vincristine can be decreased when combined with Imipramine.
Captopril Captopril Imipramine may decrease the antihypertensive activities of Captopril.
Dipyridamole Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Imipramine.
Isoxsuprine Isoxsuprine The risk or severity of hypertension can be increased when Imipramine is combined with Isoxsuprine.
Vinblastine Vinblastine The metabolism of Imipramine can be decreased when combined with Vinblastine.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Imipramine which could result in a higher serum level.
Metoprolol Metoprolol The metabolism of Imipramine can be decreased when combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Imipramine.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Imipramine is combined with Thiothixene.
Aspirin Aspirin The metabolism of Acetylsalicylic acid can be increased when combined with Imipramine.
Salsalate Salsalate Imipramine may decrease the excretion rate of Salsalate which could result in a higher serum level.
Alprazolam Alprazolam Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Temazepam Temazepam Temazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Triazolam Triazolam Triazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Dicyclomine Dicyclomine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Imipramine.
Propantheline Propantheline Imipramine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim Trimethoprim may decrease the excretion rate of Imipramine which could result in a higher serum level.
Diltiazem Diltiazem The metabolism of Imipramine can be decreased when combined with Diltiazem.
Nifedipine Nifedipine The metabolism of Imipramine can be decreased when combined with Nifedipine.
Timolol Timolol The metabolism of Timolol can be decreased when combined with Imipramine.
Verapamil Verapamil Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.
Atenolol Atenolol The metabolism of Imipramine can be decreased when combined with Atenolol.
Pindolol Pindolol The metabolism of Imipramine can be decreased when combined with Pindolol.
Cisplatin Injection Cisplatin Injection The serum concentration of Cisplatin can be increased when it is combined with Imipramine.
Diflunisal Diflunisal Imipramine may decrease the excretion rate of Diflunisal which could result in a higher serum level.
Piroxicam Piroxicam Imipramine may decrease the excretion rate of Piroxicam which could result in a higher serum level.
Bumetanide Bumetanide Bumetanide may decrease the excretion rate of Imipramine which could result in a higher serum level.
Streptozocin Streptozocin The metabolism of Imipramine can be increased when combined with Streptozocin.
Etoposide Etoposide The metabolism of Etoposide can be decreased when combined with Imipramine.
Glyburide Glyburide The metabolism of Glyburide can be decreased when combined with Imipramine.
Glipizide Glipizide Imipramine may decrease the hypoglycemic activities of Glipizide.
Indapamide Indapamide Imipramine may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin Amoxicillin Imipramine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection Nafcillin Injection The metabolism of Imipramine can be increased when combined with Nafcillin.
Oxacillin Injection Oxacillin Injection Imipramine may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Pentoxifylline Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Imipramine.
Pentamidine Injection Pentamidine Injection The metabolism of Imipramine can be decreased when combined with Pentamidine.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Imipramine which could result in a higher serum level.
Labetalol Labetalol Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Auranofin Auranofin Imipramine may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imipramine.
Gemfibrozil Gemfibrozil The metabolism of Imipramine can be decreased when combined with Gemfibrozil.
Guanabenz Guanabenz The risk or severity of hypertension can be increased when Imipramine is combined with Guanabenz.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Ketoprofen Ketoprofen Imipramine may decrease the excretion rate of Ketoprofen which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Imipramine which could result in a higher serum level.
Pimozide Pimozide The metabolism of Pimozide can be decreased when combined with Imipramine.
Enalapril Enalapril Imipramine may decrease the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen Imipramine may decrease the excretion rate of Flurbiprofen which could result in a higher serum level.
Amiodarone Amiodarone The serum concentration of Imipramine can be increased when it is combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Imipramine which could result in a higher serum level.
Buspirone Buspirone The metabolism of Buspirone can be decreased when combined with Imipramine.
Lovastatin Lovastatin The metabolism of Imipramine can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The metabolism of Imipramine can be decreased when combined with Ciprofloxacin.
Mesalamine Mesalamine Mesalazine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Diclofenac Diclofenac The metabolism of Diclofenac can be decreased when combined with Imipramine.
Fluoxetine Fluoxetine The serum concentration of Fluoxetine can be increased when it is combined with Imipramine.
Nimodipine Nimodipine The risk or severity of hypotension can be increased when Imipramine is combined with Nimodipine.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The metabolism of Imipramine can be decreased when combined with Interferon alfa-2b.
Clozapine Clozapine Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Estazolam Estazolam Estazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Idarubicin Idarubicin The metabolism of Imipramine can be decreased when combined with Idarubicin.
Ofloxacin Ofloxacin The metabolism of Imipramine can be decreased when combined with Ofloxacin.
Didanosine Didanosine Imipramine may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Imipramine may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Clarithromycin Clarithromycin The serum concentration of Clarithromycin can be increased when it is combined with Imipramine.
Benazepril Benazepril Imipramine may decrease the antihypertensive activities of Benazepril.
Etodolac Etodolac Imipramine may decrease the excretion rate of Etodolac which could result in a higher serum level.
Felodipine Felodipine The metabolism of Imipramine can be decreased when combined with Felodipine.
Fosinopril Fosinopril Imipramine may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Nabumetone Nabumetone The metabolism of Nabumetone can be decreased when combined with Imipramine.
Pravastatin Pravastatin The serum concentration of Imipramine can be increased when it is combined with Pravastatin.
Quinapril Quinapril Imipramine may decrease the antihypertensive activities of Quinapril.
Ramipril Ramipril Imipramine may decrease the antihypertensive activities of Ramipril.
Simvastatin Simvastatin The metabolism of Simvastatin can be decreased when combined with Imipramine.
Amlodipine Amlodipine The risk or severity of hypotension can be increased when Imipramine is combined with Amlodipine.
Teniposide Injection Teniposide Injection The metabolism of Imipramine can be decreased when combined with Teniposide.
Itraconazole Itraconazole The serum concentration of Imipramine can be increased when it is combined with Itraconazole.
Lisinopril Lisinopril Imipramine may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Oxaprozin Oxaprozin Imipramine may decrease the excretion rate of Oxaprozin which could result in a higher serum level.
Rifabutin Rifabutin The metabolism of Imipramine can be increased when combined with Rifabutin.
Sotalol Sotalol The metabolism of Sotalol can be decreased when combined with Imipramine.
Bisoprolol Bisoprolol Imipramine may increase the orthostatic hypotensive activities of Bisoprolol.
Zolpidem Zolpidem Zolpidem may increase the Decreased alertness activities of Imipramine.
Doxazosin Doxazosin Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Terazosin Terazosin Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Isradipine.
Omeprazole Omeprazole The metabolism of Imipramine can be decreased when combined with Omeprazole.
Cisapride Cisapride The metabolism of Imipramine can be decreased when combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Imipramine is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Imipramine can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The metabolism of Imipramine can be decreased when combined with Venlafaxine.
Nizatidine Nizatidine The therapeutic efficacy of Imipramine can be decreased when used in combination with Nizatidine.
Stavudine Stavudine Imipramine may increase the neurotoxic activities of Stavudine.
Fluvoxamine Fluvoxamine The metabolism of Imipramine can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.
Lamotrigine Lamotrigine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
Losartan Losartan The metabolism of Imipramine can be decreased when combined with Losartan.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The metabolism of Imipramine can be decreased when combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Imipramine.
Lansoprazole Lansoprazole The metabolism of Imipramine can be decreased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Imipramine.
Nicardipine Nicardipine Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Bupropion Bupropion The risk or severity of seizure can be increased when Bupropion is combined with Imipramine.
Ticlopidine Ticlopidine The metabolism of Imipramine can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The serum concentration of Imipramine can be increased when it is combined with Saquinavir.
Metformin Metformin Imipramine may decrease the hypoglycemic activities of Metformin.
Nisoldipine Nisoldipine The risk or severity of hypotension can be increased when Nisoldipine is combined with Imipramine.
Lamivudine Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Imipramine.
Riluzole Riluzole The metabolism of Riluzole can be decreased when combined with Imipramine.
Amifostine Injection Amifostine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Amifostine.
Acarbose Acarbose Imipramine may decrease the hypoglycemic activities of Acarbose.
Glimepiride Glimepiride Imipramine may decrease the hypoglycemic activities of Glimepiride.
Gemcitabine Injection Gemcitabine Injection The serum concentration of Imipramine can be increased when it is combined with Gemcitabine.
Indinavir Indinavir The metabolism of Imipramine can be decreased when combined with Indinavir.
Ritonavir Ritonavir The serum concentration of Imipramine can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Imipramine.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Meropenem Injection Meropenem Injection Imipramine may decrease the excretion rate of Meropenem which could result in a higher serum level.
Clomipramine Clomipramine The metabolism of Clomipramine can be decreased when combined with Imipramine.
Zafirlukast Zafirlukast The metabolism of Imipramine can be decreased when combined with Zafirlukast.
Fosfomycin Fosfomycin Imipramine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Mirtazapine Mirtazapine Imipramine may increase the serotonergic activities of Mirtazapine.
Trandolapril Trandolapril Imipramine may decrease the antihypertensive activities of Trandolapril.
Topiramate Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Imipramine is combined with Topiramate.
Zileuton Zileuton The metabolism of Zileuton can be decreased when combined with Imipramine.
Valsartan Valsartan Imipramine may decrease the antihypertensive activities of Valsartan.
Insulin Lispro Injection Insulin Lispro Injection The metabolism of Imipramine can be increased when combined with Insulin lispro.
Pramipexole Pramipexole Imipramine may increase the sedative activities of Pramipexole.
Donepezil Donepezil The therapeutic efficacy of Imipramine can be decreased when used in combination with Donepezil.
Nelfinavir Nelfinavir The metabolism of Imipramine can be decreased when combined with Nelfinavir.
Fexofenadine Fexofenadine The serum concentration of Imipramine can be increased when it is combined with Fexofenadine.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Imipramine.
Loratadine Loratadine Imipramine may increase the anticholinergic activities of Loratadine.
Carvedilol Carvedilol Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Nilutamide Nilutamide The metabolism of Imipramine can be decreased when combined with Nilutamide.
Flutamide Flutamide The metabolism of Flutamide can be decreased when combined with Imipramine.
Selegiline Selegiline The metabolism of Selegiline can be decreased when combined with Imipramine.
Bicalutamide Bicalutamide The metabolism of Imipramine can be decreased when combined with Bicalutamide.
Sertraline Sertraline The metabolism of Sertraline can be decreased when combined with Imipramine.
Propafenone Propafenone The metabolism of Imipramine can be decreased when combined with Propafenone.
Letrozole Letrozole The metabolism of Imipramine can be decreased when combined with Letrozole.
Raloxifene Raloxifene The metabolism of Imipramine can be decreased when combined with Raloxifene.
Irbesartan Irbesartan Imipramine may decrease the antihypertensive activities of Irbesartan.
Tamsulosin Tamsulosin Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Ropinirole Ropinirole The risk or severity of adverse effects can be increased when Imipramine is combined with Ropinirole.
Finasteride Finasteride The metabolism of Finasteride can be decreased when combined with Imipramine.
Quetiapine Quetiapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cetirizine Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Paroxetine Paroxetine The metabolism of Paroxetine can be decreased when combined with Imipramine.
Tolcapone Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Citalopram Citalopram Imipramine may increase the QTc-prolonging activities of Citalopram.
Capecitabine Capecitabine Imipramine may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Efavirenz Efavirenz The metabolism of Imipramine can be increased when combined with Efavirenz.
Abacavir Abacavir Imipramine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Sildenafil Sildenafil The metabolism of Imipramine can be decreased when combined with Sildenafil.
Pioglitazone Pioglitazone Imipramine may decrease the hypoglycemic activities of Pioglitazone.
Celecoxib Celecoxib The metabolism of Imipramine can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Imipramine can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The metabolism of Imipramine can be decreased when combined with Tolterodine.
Thalidomide Thalidomide Imipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Balsalazide Balsalazide Imipramine may decrease the excretion rate of Balsalazide which could result in a higher serum level.
Nateglinide Nateglinide The metabolism of Imipramine can be decreased when combined with Nateglinide.
Galantamine Galantamine The metabolism of Imipramine can be decreased when combined with Galantamine.
Levetiracetam Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Rabeprazole Rabeprazole The metabolism of Imipramine can be decreased when combined with Rabeprazole.
Terbinafine Terbinafine The metabolism of Imipramine can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists